<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712322</url>
  </required_header>
  <id_info>
    <org_study_id>CDAR328B2201</org_study_id>
    <nct_id>NCT00712322</nct_id>
  </id_info>
  <brief_title>2 Week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Yrs) With Neurogenic Detrusor Overactivity</brief_title>
  <official_title>A 14-day, Open-label, Multicenter, Dose-escalating, Sequential Cohort Study to Evaluate Pharmacodynamics (Urodynamics) and Pharmacokinetics, Clinical Efficacy, Tolerability and Safety, Following Multiple Doses (mg/kg/Day) of Darifenacin Liquid Oral Suspension Given b.i.d. (Twice Daily) in Children, Ages 2 - 15 Years, With Neurogenic Detrusor Overactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacodynamics and pharmacokinetics of darifenacin liquid oral
      suspension in children, ages 2-15 years, with neurogenic detrusor overactivity. The results
      will support a benefit-risk based dosage recommendation for phase IIIa clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to extremely difficult enrollment.
  </why_stopped>
  <start_date type="Actual">October 31, 2008</start_date>
  <completion_date type="Actual">May 23, 2013</completion_date>
  <primary_completion_date type="Actual">May 23, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to day 14 in the urodynamic parameter &quot;volume at first contraction&quot;, comparing multiple doses of darifenacin liquid oral suspension</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing effect of multiple doses of darifenacin liquid oral suspension, on: • Urodynamic, pharmacokinetic, efficacy parameters • Safety, tolerability</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Neurogenic Detrusor Overactivity</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estimated pediatric study doses of darifenacin liquid oral suspension: (0.030 mg/kg/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estimated pediatric study doses of darifenacin liquid oral suspension: (0.0625 mg/kg/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estimated pediatric study doses of darifenacin liquid oral suspension: (0.125 mg/kg/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estimated pediatric study doses of darifenacin liquid oral suspension: (0.250 mg/kg/day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin</intervention_name>
    <description>(0.030 mg/kg/day)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Enablex®, Emselex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin</intervention_name>
    <description>(0.0625 mg/kg/day)</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Enablex®, Emselex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin</intervention_name>
    <description>(0.125 mg/kg/day)</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Enablex®, Emselex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin</intervention_name>
    <description>(0.250 mg/kg/day)</description>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>Enablex®, Emselex®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients ages 2-15 years

          -  Documented detrusor overactivity associated with a known neurological condition such
             as meningomyelocele or spinal cord injury, and confirmed by urodynamics at baseline

          -  Using clean intermittent catheterization (CIC) on a regular basis

          -  Participating in a bowel program on a regular basis

          -  Able to swallow the study medication in accordance to the protocol

          -  Patients and/or parent/guardian able to complete the bladder diary and follow the
             study procedures

        Exclusion Criteria:

          -  Treatment with drugs known to significantly affect the urinary bladder and urinary
             bladder outlet function

          -  Fecal impaction. Patients may be included, once this condition has resolved

          -  Clinically significant anatomical abnormalities or acquired disorders of the urinary
             tract

          -  Previous reconstructive surgery (augmentation etc.) of the bladder or bladder outlet

          -  Symptomatic urinary tract infection unresolved at time of urodynamic study and/or
             completion of bladder diary.

          -  Diabetes insipidus

          -  Electro stimulation therapy or bladder training within 2 weeks prior to Visit 1 and at
             any time during the study

          -  Concomitant diseases, in which the use of darifenacin is contraindicated

          -  History of hypersensitivity to darifenacin or to drugs with similar chemical
             structures

          -  Patients with any physical and cognitive impairment or any other condition which in
             the opinion of the investigator makes the patient unsuitable for inclusion

          -  Female adolescent of child-bearing potential, unless using an acceptable method of
             contraception

          -  Pregnant or nursing (lactating) female adolescents Other protocol-defined
             inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herman Ellman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Warner Chilcott (US) LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Karp 8210</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-2119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Pediatric Urology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Urology Associates, PC</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Urology Associates PC</name>
      <address>
        <city>Tarrytown</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric &amp; Adolescent Urology, Inc Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Study Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospital Infantil, Universitario De San Jose</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Valle de Lili</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Colombia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric, Children, Urodynamics, Oral Suspension, Overactive bladder, Dose-finding, Neurogenic Detrusor Overactivity, Meningomyelocele, Spinal cord injury</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darifenacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

